- Hutchmed
- | 公告及新聞稿
2019年3月29日，中國上海 — 和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）在中國啟動了一項有註冊性潛力的IIb/III期臨床試驗，旨在對比索凡替尼（HMPL-012或sulfatinib）和卡培他濱治療一線化療後進展的晚期膽道癌（BTC）的療效和安全性。BTC是一類異質性的罕見惡性腫瘤，起源於膽道上皮和膽囊，存在巨大的未被滿足的醫療需求。2019年3月22日，首名患者開始接受索凡替尼的治療。
該研究是一項隨機、開放標籤、活性對照、多中心研究，旨在對比索凡替尼與化療藥物卡培他濱作為二線療法治療不可切除或轉移性BTC患者的療效和安全性。索凡替尼是一種小分子口服抗血管生成-免疫逃逸激酶抑制劑，可同時阻斷腫瘤血管生成和免疫逃逸。該研究的主要終點為總生存期（OS）。次要終點包括腫瘤控制相關指標，如無進展生存期（PFS）、客觀緩解率（ORR）、疾病控制率（DCR）、緩解持續時間（DOR）、生活品質、腫瘤標誌物以及安全性等。該研究的主要研究者為中國人民解放軍總醫院第五醫學中心胃腸腫瘤科徐建明教授。該研究詳情可登陸clinicaltrials.gov，檢索NCT03873532查看。
該研究是在兩項臨床試驗的基礎上對索凡替尼治療BTC的進一步探索，這兩項臨床試驗包括一項在中國以BTC為適應症的Ib/II期概念驗證研究（clinicaltrials.gov 註冊號NCT02966821），以及一項在美國以BTC和胰腺神經內分泌腫瘤（NET）為適應症的Ib期臨床試驗（clinicaltrials.gov 註冊號NCT02549937）。其中，中國Ib/II期概念驗證BTC臨床試驗的研究結果預計將於2019年提交發表。
關於索凡替尼
索凡替尼是一種新型的口服抗血管生成-免疫逃逸激酶抑制劑，可通過抑制VEGFR和成纖維細胞生長因子受體（FGFR）來抑制血管生成，索凡替尼也可抑制集落刺激因子-1受體（CSF-1R），通過抑制CSF-1R可調節腫瘤相關巨噬細胞，促進機體對腫瘤細胞的免疫應答。因為具有這種同時抑制血管生成和腫瘤免疫逃逸的作用機制，索凡替尼可能非常適合與其他免疫療法聯用。除了此次啟動的BTC研究，索凡替尼目前正在美國和中國開展多項概念驗證研究，並在中國開展了多項後期臨床試驗。
中國胰腺NET研究：2016年，和黃醫藥在中國啟動了一項關鍵性III期註冊研究SANET-p，入組患者為低級別或中級別晚期胰腺NET患者。主要研究終點為PFS。和黃醫藥計畫於2019年年底開展一項中期分析，並在2020年完成患者入組工作（clinicaltrials.gov 註冊號NCT02589821）。
中國非胰腺NET研究：2015年12月，和黃醫藥在中國啟動了索凡替尼關鍵性III期臨床試驗SANET-ep，入組患者為低級別或中級別晚期非胰腺NET患者。主要研究終點為PFS 。和黃醫藥計畫於2019年中開展一項中期分析，並在2020年完成患者入組工作（clinicaltrials.gov 註冊號NCT02588170）。
美國與歐洲胰腺NET研究：由於索凡替尼以胰腺NET為適應症的II期中國臨床試驗資料令人鼓舞（clinicaltrials.gov 註冊號NCT02267967），且美國Ib期臨床試驗進展順利，和黃醫藥決定將計畫開展索凡替尼在胰腺NET患者中的註冊性研究。
免疫聯合療法：2018年11月，和黃醫藥達成了兩項合作協定，以評估索凡替尼聯合免疫檢查點抑制劑的安全性、耐受性和療效，包括：一項與上海君實生物醫藥科技股份有限公司在全球共同開發索凡替尼與拓益®（特瑞普利單抗，JS001）聯合療法的合作協定，以及一項與泰州翰中生物醫藥有限公司在中國共同開發索凡替尼與HX008聯合療法的合作協定。拓益®為上海君實生物醫藥科技股份有限公司研發的一種PD-1單克隆抗體，已於 2018年年底在中國獲批。HX008為泰州翰中生物醫藥有限公司的在研PD-1單克隆抗體。相關安全性研究目前已經啟動/處於計畫階段，以確定呋喹替尼與拓益®或HX008組成的聯合療法的安全有效的劑量方案。
關於Chi-Med
和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）是一家創新型生物醫藥公司，致力於藥品的研究、開發、生產和銷售。和記黃埔醫藥（上海）有限公司是Chi-Med的創新藥研發平臺，現有一支約420人的研發團隊，專注於研發和商業開發治療癌症和自身免疫性疾病的靶向創新藥物和免疫療法，目前共有8個抗癌類候選藥物進入臨床階段，正在全球開展臨床研究。Chi-Med的商業平臺負責處方藥和健康類消費品在中國的生產和行銷,銷售網路覆蓋中國廣大地區醫院。
總部位於中國香港，在倫敦證券交易所（AIM）和美國納斯達克全球精選市場均已上市，由長江和記實業有限公司（SEHK：1）持有多數股權。瞭解更多詳情請訪問：www.chi-med.com
聯繫方式
投資者咨詢 |
|
| 李健鴻，資深副總裁，企業融資及發展 | +852 2121 8200 |
| David Dible, Citigate Dewe Rogerson |
+44 7967 566 919 （手提電話）david.dible@citigatedewerogerson.com |
| Xuan Yang, Solebury Trout |
+1 (415) 971 9412（手提電話） xyang@troutgroup.com |
媒體咨詢 |
|
| 英國及歐洲 – | |
| Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888（手提電話） anthony.carlisle@cdrconsultancy.co.uk |
| 美洲 — | |
| Brad Miles, Solebury Trout | +1 (917) 570 7340（手提電話） bmiles@troutgroup.com |
| 中國香港及亞洲其他地區 （不含中國大陸地區） – | |
| Joseph Chi Lo, Brunswick Zhou Yi, Brunswick |
+852 9850 5033（手提電話） jlo@brunswickgroup.com+852 9783 6894（手提電話） yzhou@brunswickgroup.com |
| 中國大陸地區 – | |
| Sam Shen, Edelman |
+86 136 7179 1029 （手提電話） sam.shen@edelman.com |
任命保薦人 |
|
| Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |
2019年3月28日，中國上海 — 和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）將於2019年3月31日-4月3日在美國佐治亞州亞特蘭大市召開的美國癌症研究協會（AACR）年會上分享沃利替尼治療肺癌的相關專案的更新資料。
一項在中國開展的沃利替尼單藥II期臨床試驗的初步療效和安全性資料將於大會上公佈，這項研究入組的患者為既往系統治療失敗或不能接受化療的攜帶MET外顯子14跳變的肺肉瘤樣癌以及其他類型非小細胞肺癌（NSCLC）患者。（摘要號 #CT031, clinicaltrials.gov 註冊號 NCT02897479）
另外，多篇沃利替尼聯合泰瑞莎®（奧希替尼）的Ib/II 期TATTON臨床研究相關摘要也將公佈。摘要關注的患者人群為表皮生長因子受體（EGFR）突變陽性且MET擴增的NSCLC患者，入組患者需既往接受過EGFR酪氨酸激酶抑制劑（TKI）治療後進展（clinicaltrials.gov 註冊號 NCT02143466）。其中，一篇摘要主要關注既往接受過第一代或第二代EGFR-TKI治療且未接受過第三代EGFR-TKI治療的患者（摘要號 #CT032）。另外一篇摘要則主要關注接受過第三代EGFR-TKI治療後仍然出現疾病進展的患者（摘要號 #CT033）。第三篇則關注MET相關EGFR-TKI耐藥性檢測手段，也將以壁報形式公佈（摘要號 #4897/20），作為對以上兩篇摘要的補充。
TATTON研究的初步結果已於2017年10月在日本橫濱舉行的第18屆世界肺癌大會（WCLC）上以口頭報告的形式公佈。[1] 基於TATTON研究的結果，一項探索沃利替尼與泰瑞莎®聯合療法治療既往服用泰瑞莎®後出現MET相關EGFR-TKI耐藥患者的II期臨床試驗SAVANNAH也已經開展（clinicaltrials.gov 註冊號 NCT03778229）。
報告詳情如下：
| 報告環節： | Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It? NSCLC耐藥性能否被攻克？ |
| 環節分類： | 臨床試驗主會環節 |
| 環節編號： | CTPL02 |
| 日期及時間： | 3月31日（周日） 3:00 PM-5:15 PM |
| 報告地點： | Marcus Auditorium, Building A, Georgia World Congress Center |
|
|
|
| 報告1： | Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations 沃利替尼治療MET外顯子14跳變肺肉瘤樣癌及其他類型NSCLC患者的初步療效和安全性結果 |
| 主要作者： | 上海交通大學附屬胸科醫院 陸舜 教授 |
| 摘要號及連結： | CT031 – 美國東部時間2019年3月29日3 PM後公佈摘要 |
| 時間： | 3:05 PM-3:30 PM |
|
|
|
| 報告2： | TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) TATTON Ib期擴展隊列：奧希替尼聯合沃利替尼治療既往第一代/第二代表皮生長因子受體（EGFR）酪氨酸激酶抑制劑（TKI）治療後進展的EGFR突變且MET擴增NSCLC患者 |
| 主要作者： | 紀念斯隆-凱特琳癌症中心腫瘤內科學家 Helena A. Yu |
| 摘要號及連結： | CT032 – 報告時公佈摘要 |
| 時間： | 3:40 PM-3:55 PM |
|
|
|
| 報告3： | TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) TATTON Ib期擴展隊列：奧希替尼聯合沃利替尼治療既往第三代表皮生長因子受體（EGFR）酪氨酸激酶抑制劑（TKI）治療後進展的EGFR突變且MET擴增NSCLC患者 |
| 主要作者： | 哈佛醫學院副教授、麻省總醫院癌症早期檢測創新中心主任 Lecia V. Sequist |
| 摘要號及連結： | CT033 – 報告時公佈摘要 |
| 時間： | 3:55 PM-4:15 PM |
| 報告環節： | Novel Strategies for Biomarker Identification and Use in Cancer 3 生物標記物檢測與應用新策略-3 |
| 壁報題目： | Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study MET導致EGFR酪氨酸激酶抑制劑（TKI）耐藥NSCLC的檢測：TATTON研究生物標記物分析 |
| 主要作者： | Ryan J. Hartmaier，阿斯利康 |
| 摘要號及連結： | 4897 / 20 – 摘要已公布 |
| 日期及時間： | 2019年4月3日，8:00 AM – 12:00 PM |
| 報告地點： | Section 19, Building B, Georgia World Congress Center （佐治亞世界會議中心B幢19區） |
關於沃利替尼
沃利替尼有潛力成為全球首創c-MET受體酪氨酸激酶抑制劑，c-MET已被證明在多種實體瘤中功能異常。和黃醫藥對沃利替尼進行了成功地設計，使其成為能夠強效、高選擇性靶向c-MET的口服抑制劑，並通過對其化學結構的修飾來避免導致其他多種c-MET抑制劑研發中斷的代謝相關腎毒性問題。截止至目前為止，共計超過900名癌症患者接受了沃利替尼的治療，沃利替尼在多種c-MET基因異常實體瘤中均展現出了令人鼓舞的臨床療效和較好的安全性。和黃醫藥目前正在與合作夥伴阿斯利康聯合開展沃利替尼單藥和聯合療法在多種實體瘤中的數項Ib/II期臨床試驗。
關於Chi-Med
和黃中國醫藥科技有限公司（Chi-Med）（AIM/Nasdaq:HCM）是一家創新型生物醫藥公司，致力於藥品的研究、開發、生產和銷售。和記黃埔醫藥（上海）有限公司是Chi-Med的創新藥研發平臺，現有一支約420人的研發團隊，專注於研發和商業開發治療癌症和自身免疫性疾病的靶向創新藥物，目前共有8個抗癌類候選藥物進入臨床階段，正在全球開展臨床研究。Chi-Med的商業平臺負責處方藥和健康類消費品在中國的生產和行銷,銷售網路覆蓋中國廣大地區醫院。
總部位於中國香港，在倫敦證券交易所（AIM）和美國納斯達克全球精選市場均已上市，由長江和記實業有限公司（SEHK：1）持有多數股權。瞭解更多詳情請訪問：www.chi-med.com
聯繫方式
投資者咨詢 |
|
| 李健鴻，資深副總裁，企業融資及發展 | +852 2121 8200 |
|
David Dible, Citigate Dewe Rogerson
|
+44 7967 566 919 （手提電話）david.dible@citigatedewerogerson.com |
|
Xuan Yang, Solebury Trout
|
+1 (415) 971 9412（手提電話） xyang@troutgroup.com |
媒體咨詢 |
|
| 英國及歐洲 – | |
| Anthony Carlisle, Citigate Dewe Rogerson |
+44 7973 611 888（手提電話） anthony.carlisle@cdrconsultancy.co.uk |
| 美洲 — | |
| Brad Miles, Solebury Trout |
+1 (917) 570 7340（手提電話） bmiles@troutgroup.com |
| 中國香港及亞洲其他地區 （不含中國大陸地區） – | |
|
Joseph Chi Lo, Brunswick Zhou Yi, Brunswick |
+852 9850 5033（手提電話） jlo@brunswickgroup.com +852 9783 6894（手提電話） yzhou@brunswickgroup.com |
| 中國大陸地區 – | |
|
Sam Shen, Edelman
|
+86 136 7179 1029 （手提電話） sam.shen@edelman.com |
任命保薦人 |
|
| Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |
| 地址： 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN, UK |
| 時間：上午11時 |
地址：香港港麗酒店
地址：摩根士丹利香港辦公室
London: Monday, March 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2018 annual report of Chi-Med on March 21 2019, the following awards granted under the Long Term Incentive Plan (“LTIP”) on October 19, 2015 to Mr Christian Hogg, Mr Johnny Cheng and Dr Weiguo Su were vested on March 22, 2019:-
| Award Holders |
Number of American depositary shares (“ADS”) |
|
| Person Discharging Managerial Responsibilities | ||
| Mr Christian Hogg (Executive Director and Chief Executive Officer) |
8,234 |
|
| Mr Johnny Cheng (Executive Director and Chief Financial Officer) |
2,540 |
|
| Dr Weiguo Su (Executive Director and Chief Scientific Officer) |
3,008 |
|
| Total |
13,782 |
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
(a) Mr Christian Hogg
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Mr Christian Hogg | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Director and Chief Executive Officer | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Hutchison China MediTech Limited | ||||
| b) | LEI | 2138006X34YDQ6OBYE79 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) |
Description of the financial instrument, type of instrument Identification code |
ADS each representing one half of one Ordinary Share of US$1.00ADS ISIN: US44842L1035 |
||||
| b) | Nature of the transaction | Vesting of awards granted on October 19, 2015 under Chi-Med’s LTIP | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information
|
N/A | ||||
| e) | Date of the transaction | 2019-03-22 | ||||
| f) | Place of the transaction | Nasdaq Stock Market | ||||
(b) Mr Johnny Cheng
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Mr Johnny Cheng | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Director and Chief Financial Officer | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Hutchison China MediTech Limited | ||||
| b) | LEI | 2138006X34YDQ6OBYE79 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) |
Description of the financial instrument, type of instrument Identification code |
ADS each representing one half of one Ordinary Share of US$1.00ADS ISIN: US44842L1035 |
||||
| b) | Nature of the transaction | Vesting of awards granted on October 19, 2015 under Chi-Med’s LTIP | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information
|
N/A | ||||
| e) | Date of the transaction | 2019-03-22 | ||||
| f) | Place of the transaction | Nasdaq Stock Market | ||||
(c) Dr Weiguo Su
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Dr Weiguo Su | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Director and Chief Scientific Officer | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Hutchison China MediTech Limited | ||||
| b) | LEI | 2138006X34YDQ6OBYE79 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) |
Description of the financial instrument, type of instrument Identification code |
ADS each representing one half of one Ordinary Share of US$1.00ADS ISIN: US44842L1035 |
||||
| b) | Nature of the transaction | Vesting of awards granted on October 19, 2015 under Chi-Med’s LTIP | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information
|
N/A | ||||
| e) | Date of the transaction | 2019-03-22 | ||||
| f) | Place of the transaction | Nasdaq Stock Market | ||||
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 420 scientists and staff focusing on discovering, developing and commercializing targeted therapies and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.chi-med.com).
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 420 scientists and staff focusing on discovering, developing and commercializing targeted therapies and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
Contents
Corporate Information
2018 Key Highlights
Highlights
Chairman’s Statement
Financial Review
Operations Review
Biographical Details Of Directors
Report of the Directors
Corporate Governance Report
Form 20-F (Including Financial Statements)
Information For Shareholders
London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2018. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/4831S_1-2019-3-11.pdf and also on the website of the Company at www.chi-med.com.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 420 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs.
Video webcast presentation at 9:00 a.m. GMT and additional conference call at 9:00 a.m. EDT.
- Fruquintinib (Elunate®)
- Received New Drug Application (“NDA”) approval for fruquintinib and launched in late November 2018 for colorectal cancer (“CRC”), the first ever China-discovered novel oncology drug to receive full NDA approval in China; and
- Completed an agreement with Eli Lilly and Company (“Lilly”) to amend the original 2013 license and collaboration agreement for fruquintinib enabling both parties to maximize its long-term commercial potential in China.
- Savolitinib
- Initiated two studies with potential for registration in lung cancer:
(1) China Phase II in mesenchymal epithelial transition receptor (“MET”) exon 14 mutation/deletion non-small cell lung cancer (“NSCLC”); and
(2) Global Tagrisso®/savolitinib combination Phase II in MET-positive Tagrisso® refractory NSCLC.
- Presented Phase II data of Imfinzi®/savolitinib combination in papillary renal cell carcinoma (“PRCC”), a tolerable combination with immature but encouraging efficacy.
- Initiated two studies with potential for registration in lung cancer:
- Hematological malignancies: Expanded Phase I/Ib dataset in Australia and China in lymphoma for HMPL-523 targeting spleen tyrosine kinase (“Syk”) and HMPL-689 targeting phosphoinositide 3-kinase delta (“PI3Kδ”). Cleared U.S. Investigational New Drug (“IND”) applications on both assets with U.S. and E.U. clinical development set to start in H1 2019.
- Immunotherapy combinations: Signed four co-development collaborations for fruquintinib and surufatinib in combination with various programmed cell death protein-1 (“PD-1”) monoclonal antibodies.
- Global clinical development: Expansion of U.S. and international clinical and regulatory operations firmly underway with five Chi-Med drug candidates either in or about to start global clinical development.
“With the launch of Elunate® underway and doing well, and with its financial prospects enhanced by the recent Lilly amendment, we are focused on our broader late-stage clinical development program with multiple important opportunities being pursued in parallel,” said Simon To, Chairman, Chi-Med. “We took a big step in 2018 to expand our U.S. development capability in order that we can take full advantage of the global potential of our assets. We also entered the immuno oncology arena through multiple development collaborations combining PD-1 antibodies with our highly selective small molecules. The increased investment in all these activities is partially offset by robust income from our commercial operation in China, which also serves as a very powerful platform for future product launches.”
“Looking ahead, we target multiple NDAs in the coming two or three years, covering savolitinib, surufatinib and fruquintinib, as well as registration studies with our hematological cancer assets. We believe that these activities will address a broad range of unmet medical needs and benefit a large number of patients.”
Financial Highlights
The items below are selected financial data for the year ended December 31, 2018. All dollars are expressed in US dollar currency unless otherwise stated. For more details, please refer to “Financial Review”, “Operations Review” and “Audited Consolidated Financial Statements” below.
OVERALL GROUP: in-line with our most recent guidance
- Group revenue of $214.1 million (2017: $241.2m).
- Net loss attributable to Chi‑Med of $74.8 million (2017: net loss $26.7m).
- Adjusted Group net cash flow (non-GAAP) was -$57.3 million in 2018. Cash from our Commercial Platform, as well as payments received from our multi-national partners, offset more than half of our research and development (“R&D”) expenses.
- Cash resources of $420.3 million at Group level as of December 31, 2018 ($479.6m as of December 31, 2017), including cash and cash equivalents, short-term investments and unutilized bank facilities.
INNOVATION PLATFORM: increased investment in R&D driven by expansion of our operations and progress on our clinical development pipeline
- Consolidated revenue was $41.2 million (2017: $36.0m) mainly from service fee payments from AstraZeneca AB (publ) (“AstraZeneca”), Lilly and Nutrition Science Partners Limited (“NSP”), our 50/50 joint venture with Nestlé Health Science S.A., and $13.5m in milestone payments from Lilly following fruquintinib approval. Following fruquintinib’s launch, under the brand name Elunate®, we recorded revenue of $3.3m and royalty income of $0.3m during the last five weeks of 2018.
- R&D expenses on an as adjusted (non-GAAP) basis increased to $142.2 million (2017: $88.0m), primarily driven by the progress in the development of our eight clinical drug candidates, five of which are now in development outside China; investment in the establishment of small molecule manufacturing operations in China; and expansion of U.S. and international clinical and regulatory operations.
- Net loss from our Innovation Platform attributable to Chi-Med of $102.4 million (2017: net loss of $51.9m).
COMMERCIAL PLATFORM: continued solid net income growth amid shift in revenue model and over-the-counter (“OTC”) logistics divestment
- Total consolidated sales fell 16% to $172.9 million (2017: $205.2m) because of the implementation of the Two-Invoice System in China, a new government policy that led to a shift in our revenue recognition for certain third-party drugs from gross sales consolidation to a fee-for-service revenue model. This new Two-Invoice System policy did not affect our total consolidated net income in 2018.
- Total sales of non-consolidated joint ventures, on an as adjusted (non-GAAP) basis excluding the effects of the divestment of certain non-core operations, up 13% to $491.5 million (2017: $433.3m) driven by strong growth across major product categories.
- Total consolidated net income from our Commercial Platform attributable to Chi-Med up 10% to $41.4 million (2017: $37.5m), on an as adjusted (non-GAAP) basis excluding one-time gains in 2017.
—
U.K. Analysts Meeting and Webcast Scheduled Today at 9:00 a.m. GMT (5:00 p.m. HKT) – at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, U.K. Investors may participate in the call at +44 20 3003 2666 (800 900 476 toll free in Hong Kong), or access a live video webcast of the call via Chi-Med’s website at www.chi-med.com/investors/event-information/.
U.S. Conference Call Scheduled Today at 9:00 a.m. EDT – to participate in the call from the U.S., please dial 1 866 966 5335.
Additional dial-in numbers are also available at Chi-Med’s website. For both calls please use conference ID “Chi-Med.”
—
Innovation Platform — Operating HIGHLIGHTS
The points below summarize some of the pipeline development highlights during 2018 and to-date in 2019. For more details, please refer to “Operations Review – Innovation Platform” below.
FRUQUINTINIB – Highly selective tyrosine kinase inhibitor (“TKI”) of vascular endothelial growth factor receptor (“VEGFR”) 1/2/3 – focus on maximizing commercial potential of our first approved drug:
- FRESCO China Phase III in third-line CRC, potentially best-in-class in terms of both efficacy and safety.
- China NDA – approval and launch: received full approval for launch of fruquintinib (under the brand name Elunate®) in CRC in September 2018, including Good Manufacturing Practice (“GMP”) certification of our manufacturing facility in Suzhou. In partnership with Lilly, we launched fruquintinib in China in late November 2018 in a series of national launch meetings across China;
- Material financial impact: during 2018 Chi-Med recognized revenue from Lilly totaling $26.9 million including $14.0 million in milestone and upfront payments, $9.3 million service fees and costs, and $3.6 million in revenue from product purchases and royalties since the late-November 2018 launch;
- JAMA publication: in June 2018, the full FRESCO results were published in the Journal of the American Medical Association (“JAMA”), which we believe to be the first China-based novel oncology therapy Phase III trial to be published in the JAMA, a landmark achievement; and
- Two further analyses of FRESCO data presented at the annual meeting of the American Society of Clinical Oncology (“ASCO”) in June 2018: (1) a subgroup analysis by prior anti-VEGF or anti-epidermal growth factor receptor (“EGFR”) target therapy showed that fruquintinib had clinically meaningful benefits regardless of prior targeted therapy (PTT) without observed cumulative toxicity; and (2) an ad-hoc analysis of quality-adjusted time without symptoms or toxicity (“Q-TWiST”) showed relative improvement of Q-TWiST with fruquintinib, representing a potentially clinically important quality-of-life benefit for patients;
- 2018 Lilly Amendment: an important amendment to the original 2013 agreement that we believe secures the long-term commercial potential fruquintinib. Chi-Med will pay the full cost of any future clinical development in China. In return, Chi-Med gains:
- Full freedom to operate in selecting and pursuing any future indications in China;
- Materially higher milestones and royalties;
- Freedom to collaborate with any third-party in clinical development; and
- Possible promotion rights in 30-40% of China for fruquintinib, based on territorial sales. This transition is not expected before 2021. Until then, Lilly is responsible for all costs associated with the launch and commercialization of fruquintinib in China. If Chi-Med assumes fruquintinib promotion in the 30-40% of China, we will receive service fees, which we expect to be net income accretive to Chi-Med.
- FALUCA China Phase III in third-line NSCLC: completed enrollment of 527 patients and in November 2018 we read-out top-line results in which fruquintinib demonstrated tolerable safety and strong anti-tumor efficacy in NSCLC, meeting all secondary endpoints, however it did not achieve its primary overall survival (“OS”) endpoint;
- Global clinical development: Chi-Med retains all rights to fruquintinib outside of China. In 2018, the U.S. recommended Phase II dose for fruquintinib was determined to be the same as the dose in China. Planning is ongoing for a Phase II/III registration study in CRC in the U.S. / Europe in addition to multiple exploratory studies of fruquintinib in the U.S.; and
- PD-1 collaborations: in late 2018 we entered into collaboration agreements with Innovent Biologics (Suzhou) Co. Ltd. (“Innovent”) globally and Genor Biopharma Co. Ltd. (“Genor”) in China to explore fruquintinib in combination with their respective PD-1 monoclonal antibodies Tyvyt® (sintilimab) and genolimzumab. Safety run-in studies are now underway/being planned.
SAVOLITINIB – Highly selective TKI of MET:
- Lung cancer – MET is an increasingly important target in NSCLC both in first-line and as a major resistance mechanism in EGFR TKI-refractory patients
- In EGFR-TKI refractory NSCLC: following ongoing encouraging data in the TATTON Phase Ib/II studies in late 2018, AstraZeneca proceeded with initiation of SAVANNAH, a Phase II study of the Tagrisso® / savolitinib combination therapy in MET-positive, third-generation EGFR TKI-refractory NSCLC (principally second-line and third-line after Tagrisso®). SAVANNAH is a global study in North and South America, Europe and Asia which, subject to positive clinical outcome, is designed to support potential NDA submission. Primary data completion is anticipated in 2021;
- In MET Exon 14 mutation/deletion NSCLC: China Phase II registration intent study is ongoing with primary data completion anticipated in 2020 and potential to be the first NDA for savolitinib.
- Kidney cancer – immunotherapy combinations rapidly changing the treatment landscape in RCC
- CALYPSO Phase II combination of savolitinib with Imfinzi® programmed death-ligand 1 (“PD-L1”) inhibitor: interim data for the PRCC cohort of the CALYPSO Phase II study were presented last month at the 2019 American Society of Clinical Oncology Genitourinary Symposium (“ASCO GU”) reporting an objective response rate (“ORR”) of 27% (11/41). For previously untreated patients ORR was 32% (9/28). The savolitinib / Imfinzi® combination was tolerable. Investigators concluded that the combination is associated with durable responses in PRCC and that both progression free survival (“PFS”) and OS data were immature but encouraging. This compares to savolitinib monotherapy which reported a 7% ORR in PRCC patients (18% ORR in MET-positive; and 0% ORR in MET-negative) in a previously reported Phase II study; and
- SAVOIR Phase III in MET-positive PRCC: AstraZeneca and Chi-Med decided to suspend enrollment in the SAVOIR study due to multiple factors. These included our molecular epidemiology study which as well as emerging favorable data in PRCC for immunotherapies. We intend to reassess PRCC strategy in favor of potential combinations of savolitinib and immunotherapy.
SURUFATINIB (HMPL-012 or sulfatinib) – unique angio-immuno kinase inhibitor of VEGFR, fibroblast growth factor receptor (“FGFR”) 1, and colony stimulating factor-1 receptor (“CSF-1R”):
- China Phase IIIs in neuroendocrine tumor (“NET”): enrollment continued in the two Phase III registration studies in pancreatic-NET patients (SANET-p) as well as the broader non-pancreatic-NET population (SANET-ep). Interim analyses are expected for 2019; if results are positive and support NDA submission in early 2020, surufatinib could potentially be Chi-Med’s first novel drug candidate to be launched by our own commercial team;
- China Phase II/III in biliary tract cancer (“BTC”): based on our Phase Ib study, planning is close to complete for a randomized, open-label Phase II/III study to evaluate efficacy and safety of surufatinib in second line BTC patients in comparison to capecitabine. Study initiation is expected imminently;
- U.S. Phase Ib expansion: our U.S. dose escalation study completed in 2018 and a Phase Ib dose expansion study in NET and BTC patients is ongoing;
- PD-1 collaborations: in late 2018 we signed collaboration agreements with Shanghai Junshi Biosciences Co. Ltd. (“Junshi”) globally and Taizhou Hanzhong Pharmaceuticals, Inc. (“Hanzhong”) in China to explore surufatinib in combination with their respective PD-1 monoclonal antibodies Tuoyi® (toripalimab) and HX008. The safety run-in study of surufatinib plus Tuoyi® is now underway.
Further progress in early/proof-of-concept clinical trials, including:
- HMPL-523 – highly selective Syk TKI:
- Non-Hodgkin’s lymphoma: a Phase Ib dose expansion study is ongoing in both China and Australia in multiple sub-types of non-Hodgkin’s lymphoma including chronic lymphocytic leukemia; small lymphocytic lymphoma; follicular lymphoma; marginal zone lymphoma; diffuse large B-cell lymphoma; and mantle cell lymphoma;
- Gained U.S. clearance for IND application; and
- Initiated a Phase I study in combination with azacitidine, an approved hypo methylation agent, in elderly patients with acute myeloid leukemia in China. Dose escalation is now ongoing.
- HMPL-689 a highly selective PI3Kδ TKI: a Phase I dose escalation study is approaching completion in China in non-Hodgkin’s lymphoma patients; and our U.S. IND application has also been cleared.
- Epitinib Phase Ib/II in EGFR gene amplified glioblastoma, a type of primary brain cancer: a dose escalation study was initiated in China in the first quarter of 2018 with epitinib.
Expansion of U.S. and international operations, and recruitment of key personnel: established new office in New Jersey to support our multiple unpartnered compounds through proof-of-concept and registration trials outside of Asia.
Innovation Platform — KEY EVENTS IN 2019
- Early 2019:
- Savolitinib – Phase Ib/II data (CALYPSO) – PRCC cohort dataset for the Imfinzi® / savolitinib combination presented at ASCO GU (February 2019);
- Surufatinib – Phase I start – PD-1 combinations – initiate China safety run-in study for surufatinib combination with Tuoyi®;
- Savolitinib – Phase Ib/II data (TATTON) – presentation of Tagrisso® / savolitinib combination updated interim dataset in MET positive EGFR TKI refractory NSCLC at the 2019 American Association of Cancer Research (“AACR”) conference in March 29 to April 3, 2019;
- Savolitinib – Phase II data – MET Exon 14 NSCLC – preliminary China Phase II data to be presented at the 2019 AACR conference;
- Fruquintinib – Phase III interim analysis (FRUTIGA) – interim analysis for futility in second-line gastric cancer Phase III in China of fruquintinib / Taxol® (paclitaxel) combination;
- Surufatinib – Phase II/III start – expected start of China Phase II/III study in biliary tract cancer;
- HMPL-523 (Syk) – Phase I start – expected start of U.S. / E.U. Phase I/Ib study in indolent non-Hodgkin’s lymphoma;
- Fruquintinib – Phase I start – PD-1 combinations – initiate China safety run-in studies for fruquintinib combinations with Tyvyt® and genolimzumab; and
- HMPL-689 (PI3Kδ) – Phase I start – expected start of U.S. / E.U. Phase I/Ib study in indolent non-Hodgkin’s lymphoma.
- Mid-2019:
- Savolitinib – Phase II data (VIKTORY) – publication of the results of Phase II umbrella trial in metastatic gastric cancer based on tumor molecular profiling with MET-positive patients represented in three out of twelve VIKTORY treatment arms;
- Surufatinib – Phase III interim analysis (SANET-ep) – planned interim analysis in non-pancreatic NET Phase III in China of surufatinib monotherapy; and
- Fruquintinib – Phase III data (FALUCA) – intend to submit full analysis of third-line NSCLC registration study for presentation at a scientific conference.
- Late-2019:
- Savolitinib – Enrollment completion – expect to complete enrollment of China Phase II registration study in MET Exon 14 NSCLC;
- Fruquintinib – Phase II/III start – expected initiation of U.S. / E.U. Phase II/III study in metastatic CRC;
- HMPL-523 – Registration study start – expected initiation of China registration study in indolent non-Hodgkin’s lymphoma;
- Surufatinib – Phase Ib/II data – submit for publication of the results of Phase Ib/II study in biliary tract cancer in China; and
- Surufatinib – Phase III interim analysis (SANET-p) – planned interim analysis in pancreatic NET Phase III in China of surufatinib monotherapy.
Commercial Platform — Operating Highlights
The points below summarize some of the operational and financial highlights of our Commercial Platform during 2018. For more details, please refer to “Operations Review — Commercial Platform” below.
Large-scale, high-performance drug marketing and distribution platform covering ~320 cities/towns in China with approximately 3,400 sales personnel. Targeting multiple indications with several household-name brands:
- Sales of our non-consolidated Prescription Drugs joint venture, Shanghai Hutchison Pharmaceuticals Limited (“SHPL”) grew by 13% to $275.7 million (2017: $244.6m). SHPL’s main product, She Xiang Bao Xin (“SXBX”) pill, an oral vasodilator and pro-angiogenesis prescription therapy approved to treat coronary artery disease, saw sales increase by 11% to $233.1 million.
- Our consolidated Prescription Drugs business, operated through Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited (“Hutchison Sinopharm”), saw sales decrease by 20% to $132.8 million (2017: $166.4m) as a result of the Chinese government’s phased implementation of the new Two-Invoice System, pursuant to which Hutchison Sinopharm had converted to earning service fees from the commercialization of certain third-party products instead of recognizing the gross sales; regardless of the Two-Invoice System change, sales performance on key third-party products, such as Seroquel®, was strong resulting in 51% growth in service fees to $17.2 million (2017: $11.4m);
- Sales of our non-consolidated Consumer Health joint venture, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), grew by 14% to $215.8m (2017: $188.8m, excluding divested operations), driven by progress on certain secondary products.
- Our consolidated Consumer Health sales increased by 3% to $40.1 million (2017: $38.8m).
FINANCIAL GUIDANCE
We provide streamlined Financial Guidance for 2019.
The ramp-up of manufacturing and royalty revenues from Lilly on Elunate® is expected to significantly benefit the Company’s financial results in years to come, with a gradual start in 2019 – the product’s first full year on the market. On the broader Innovation Platform, we plan to continue to increase our investment in R&D particularly on clinical development of our main assets in the U.S. and Europe as well as in China (as discussed in the “Product pipeline progress” section below).
On the Commercial Platform, we expect to continue to generate cash flow directly through our subsidiaries and via dividends from our joint ventures. Two government reforms, the Two-Invoice System and the 4+7 Quality Consistency Evaluation (“QCE”) System, could narrow growth rates this year before having a positive mid- to long-term impact for Chi-Med (both reforms are discussed in detail the “Commercial Platform,” section below).
| 2019 Guidance | |
| Research & Development Expenses | $(160) – (200) million |
| Adjusted (non-GAAP) Group Net Cash Flow excluding financing activities | $(120) – (150) million |
2019 U.S. dollar guidance takes into account the weakening of the RMB, which is down 5% relative to the first half average last year due to global macroeconomic factors.
Use of Non-GAAP Financial Measures – References in this announcement to adjusted R&D expenses, adjusted consolidated net income attributable to Chi-Med from our Commercial Platform, adjusted consolidated operating profit from our Commercial Platform, adjusted consolidated net income attributable to Chi-Med from our Prescription Drugs business, adjusted revenues of HBYS and non-consolidated joint ventures, adjusted service fees for Seroquel®, adjusted Group net cash flows and adjusted Group net cash flows excluding financing activities are based on non-GAAP financial measures. Please see the “Use of Non-GAAP Financial Measures and Reconciliation” below for further information relevant to the interpretation of these financial measures and reconciliations of these financial measures to the most comparable GAAP measures, respectively.
FINANCIAL STATEMENTS
Chi-Med will today file with the U.S. Securities and Exchange Commission its Annual Report on Form 20-F.
ANNUAL GENERAL MEETING
The Annual General Meeting of Chi-Med will be held at 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN on Wednesday, April 24, 2019 at 11:00 a.m.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 420 scientists and staff focusing on discovering, developing and commercializing targeted therapies and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development
+852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development
+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
Media Enquiries
UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas – Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick
+852 9850 5033 (Mobile)
Hong Kong & Asia ex-China – Zhou Yi, Brunswick
+852 9783 6894 (Mobile)
Mainland China – Sam Shen, Edelman
+86 1367 179 1029 (Mobile)
Nominated Advisor
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited
+44 (20) 7886 2500
References
Unless the context requires otherwise, references in this announcement to the “Group,” the “Company,” “Chi-Med,” “Chi-Med Group,” “we,” “us,” and “our,” mean Hutchison China MediTech Limited and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context.
Past Performance and Forward-Looking Statements
The performance and results of operations of the Group contained within this announcement are historical in nature, and past performance is no guarantee of future results of the Group. This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “pipeline,” “could,” “potential,” “believe,” “first-in-class,” “best-in-class,” “designed to,” “objective,” “guidance,” “pursue,” or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such drug candidates will achieve any particular revenue or net income levels. In particular, management’s expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including the inability to meet our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; the inability of a drug candidate to meet the primary or secondary endpoint of a study; the inability of a drug candidate to obtain regulatory approval in different jurisdictions or gain commercial acceptance after obtaining regulatory approval; global trends toward health care cost containment, including ongoing pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes, and government investigations generally; and general economic and industry conditions, including uncertainties regarding the effects of the persistently weak economic and financial environment in many countries and uncertainties regarding future global exchange rates. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med is providing the information in this announcement as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
In addition, this announcement contains statistical data and estimates that Chi-Med obtained from industry publications and reports generated by third-party market research firms. Although Chi-Med believes that the publications, reports and surveys are reliable, Chi-Med has not independently verified the data and cannot guarantee the accuracy or completeness of such data. You are cautioned not to give undue weight to this data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above.
Inside Information
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
The content above is a copy of the first section of the announcement. For the remainder, including Financial Review, Operations Review, Non-GAAP Financial Measures and Reconciliation, and Consolidated Financial Statements, please download the Full Announcement.
| Announcement released: 7am BST (3pm HKT / 3am EDT) |
| >> See announcement here |
| Presentation webcast & call: 9am BST (5pm HKT / 5am EDT) |
| >> Click here for the webcast |
| US conference call: 9am EDT (1pm BST/9pm HKT) |
| — |
To participate by phone, please use one of the following numbers. The conference ID for the calls is “Chi-Med“.
| UK Toll Free | 0808 109 0700 |
| USA Toll Free | 1 866 966 5335 |
| China Toll Free | 4001 200558 |
| Hong Kong Toll Free | 800 900 476 |
| Italy Toll Free | 800 986 477 |
| Singapore Toll Free | 800 120 4789 |
| Switzerland Toll Free | 0800 800 038 |
| New York City Local Access | +1 646 843 4608 |
| London/Other International | +44 (0) 20 3003 2666 |